1. Kuleshova M.V., Pankov V.A., Dyakovich M.P., Rukavishnikov V.S., Slivnitsyna N.V., Kazakova P.V., Bochkin G.V. Vibration disease in workers of aircraft construction enterprise: factors of formation, clinical manifestations, socio-psychological peculiarities. Gigiena i sanitariya = Hygiene and Sanitation. 2018;97(10):915-920. [In Russian]. https://doi.org/10.18821/0016-9900-2018-97-10-915-920
2. Khomenko A.O., Yakshina N.V., Mushnikov V.S., Ilyin S.M., Samarskaya N.A., Chekmareva M.A. The influence of vibroacoustic factors on the safety and health of industrial employees. Ekonomika truda = Labor Economics. 2022;9(12);2175-2196. [In Russian]. https://doi.org/10.18334/et.9.12.116410
3. Chistova N.P., Masnavieva L.B., Kudaeva I.V. Vibration disease: exposure level and duration-dependent characteristics and features of the clinical picture following local and combined local and whole body vibration. Zdorov’ye naseleniya i sreda obitaniya = Public Health and Life Environment. 2021;29(12):30-35. [In Russian]. https://doi.org/10.35627/2219-5238/2021- 29-12-30-35
4. Chebotarev A.G. Working environment and occupational morbidity of mine personnel. Gornaya promyshlennost’ = Mining industry. 2018;(1):92-95. [In https://doi.org/ian].doi: 10.30686/1609-9192-2018-1-137-92-95
5. Yamshchikova A.V., Fleishman A.N., Shumeiko N.I., Gidayatova M.O. The valuation of microcirculatory and metabolic disorders in the patients with vibration disease. Sibirskiy meditsinskiy zhurnal (Irkutsk) = Siberian Medical Journal (Irkutsk). 2017;149(2):27-30. [In Russian].
6. Ali K., Sharma G., Raza N., Mufti A. Potential risk of developing peripheral neuropathy in heavy motor driving: Across-sectional study. J. Clin. Diagnostic. Res. 2020;14(11):15-20. https://doi.org/10.7860/JCDR/2020/46386.14276
7. Tekavec E., Löfqvist L., Larsson A., Fisk K., Riddar J., Nilsson T., Nordander C. Adverse health manifestations in the hands of vibration exposed carpenters - a cross sectional study. J. Occup. Med. Toxicol. 2021;16(1):16. https://doi.org/10.1186/s12995-021-00305
8. Vasyuk Yu.A., Shupenina E.Yu., Yushchuk E.N., Namazova G.A. Modern fixed combinations of antihypertensive drugs in the treatment of arterial hypertension and obesity: can this comorbid pathology be effec tively controlled? Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2019;24(9):14-21. [In Russian]. https://doi.org/10.15829/1560-4071-2019-9-14-21
9. Rakhmanova O.V. The severity of oxidative, nitrosative and carbonyl stresses in patients of different ages with arterial hypertension. Zdorov’ye i obrazovaniye v XXI veke = Health and Education in the 21st Century. 2018;20(5):25-29. [In Russian]. https://doi.org/10.26787/nydha-2226-7425-2018-20-5-25-29
10. Abdieva Yu.A., Agzamova G.S. Risk factors and features of coronary heart disease and arterial hypertension in concert production. Travmatologiya, ortopediya i reabilitatsiya = Traumatology, Orthopedics and Rehabilitation. 2022;(1):121-130.[In Russian].
11. Tretyakov S.V. Condition of cardiovascular system under vibration (clinical and pathogenetic aspects). Mezhdunarodnyy nauchno-issledovatel’skiy zhurnal = International Research Journal. 2023;(9):1-20. [In Russian]. https://doi.org/10.23670/IRJ.2023.135.38
12. Yamshchikova A.V., Fleishman A.N., Gidayatova M.O. Co-morbid conditions in the vibration disease patients. Gigiena i sanitariya = Hygiene and Sanitation. 2019;98(7):718-722. [In Russian]. https://doi.org/10.18821/0016-9900-2019-98-7-718-722
13. Yamshchikova A.V., Fleishman A.N., Gidayatova M.O., Kungurova A.A. Indicators of the relationship between heart rate variability and levels of glycemia and cholesterol in vibration pathology. Meditsina truda i promyshlennaya ekologiya = Occupational Medicine and Industrial Ecology. 2019;59(6): 359-363. [In Russian]. https://doi.org/10.31089/1026-9428-2019-59-6-359-363
14. Babanov S.A., Baraeva R.A., Strizhakov L.A., Moiseev S.V., Fomin V.V. The state of cytokine regulation and endothelial dysfunction in the combined course of vibration disease and arterial hypertension. Terapevticheskiy arkhiv = Therapeutic Archive. 2021;96(6):693-698. [In Russian]. https://doi.org/10.26442/00403660.2021.06.200880
15. Boklazhenko E.V., Bodienkova G.M. Imbalance in lymphocyte composition and cytokine profile as a risk factor of vibration disease. Analiz riska zdorov’yu = Health Risk Analysis. 2022;(1):140-145. [In Russian]. https://doi.org/10.21668/health.risk/2022.1.15
16. Leiderman I.N., Gritsan A.I., Zabolotskikh I.B., Lomidze S.V., Mazurok V.A., Nekhaev I.V., Nikolaenko E.M., Nikolenko A.V., Polyakov I.V., Sytov A.V., Yaroshetsky A.I. Perioperative nutritional support. Clinical guidelines. Vestnik intensivnoy terapii = Bulletin of Intensive Care. 2018;(3):5-21. [In Russian]. https://doi.org/10.21320/1818-474X-2018-3-5-21
17. Smirnova E.L., Poteryayeva E.L., Nikiforova N.G. Individual features of lipid peroxidation and antioxidant defence in vibration disease patients at post-contact period. Meditsina truda i promyshlennaya ekologiya = Occupational Medicine and Industrial Ecology = Occupational Medicine and Human Ecology. 2010;(8):36-40. [In Russian].
18. Malyutina N.N., Bolotova A.F., Eremeev R.B., Gilmanov A.Zh., Sosnin D.Yu. Antioxidant status of blood in patients with vibration disease. Meditsina truda i promyshlennaya ekologiya = Occupational Medicine and Industrial Ecology.2019;59(12):978-982. [In Russian]. https://doi.org/10.31089/1026-9428-2019-59-12-978-982
19. Elijovich F., Weinberger M.H., Anderson C.A., Appel L.J., Bursztyn M., Cook N.R., Dart R.A., Newton-Cheh C.H., Sacks F.M., Laffer C.L.; American Heart Association Professional and Public Education Committee of the Council on Hypertension; Council on Functional Genomics and Translational Biology; and Stroke Council.. Salt sensitivity of blood pressure: a scientific statement from the American Heart Association. Hypertension. 2016;68(3):7-46. https://doi.org/10.1161/HYP.0000000000000047
20. Kurtz T.W., diCarlo S.E., Pravenec M., Morris R.C. Jr. The American Heart Association Scientific Statement on salt sensitivity of blood pressure: Prompting consideration of alternative conceptual frameworks for the pathogenesis of salt sensitivity? J. Hypertens. 2017;35(11):2214-2225. https://doi.org/10.1097/HJH.0000000000001458
21. Shilov A.M., Knyazeva L.V. Potassium and magnesium deficiency as a risk factor for cardiovascular diseases. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2013;21(5):278-281. [In Russian].
22. Bereza I.A., Amromina A.M., Shaikhova D.R., Shastin A.S., Gazimova V.G., Astakhova S.G., Sutunkova M.P. Elationship of the superoxide dismutase 2 (SOD2) gene Ala16Val polymorphism with risk factors for the cardiovascular disease in iron and steel production employees. Gigiena i sanitariya = Hygiene and Sanitation. 2023;102(5):457-461. [In Russian]. https://doi.org/10.47470/0016-9900-2023-102-5-457-461
23. Oganov R.G., Simanenkov V.I., Bakulin I.G., Bakulina N.V., Barbarash O.L., Boytsov S.A., Boldueva S.A., Garganeeva N.P., Doshchitsin V.L., Karateev A.E., … Shalnova S.A. Comorbidities in clinical practice.Algorithms of diagnosis and treatment. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2019;18(1):5-66. [In Russian]. https://doi.org/10.15829/1728-8800-2019-1-5-66
24. Gerasimenko O.N., Shpagina L.A., Gorbunova A.M., Shpagin I.S., Sergeeva Ya.S. Clinical, functional and molecular characterization of comorbid pathology (vibration disease combined with arterial hypertension). Ateroskleroz = Atherosclerosis. 2022;18(1):68-75. [In Russian]. https://doi.org/10.52727/2078-256X-2022-18-1-68-75
25. Chumakova G.A., Kuznetsova T.Yu., Druzhilov M.A., Veselovskaya N.G. Visceral adiposity as a global factor of cardiovascular risk. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2018;23(5):7-14. [In Russian]. https://doi.org/10.15829/1560-4071-2018-5-7-14
26. Shupenina E.Yu., Yushchuk E.N., Vasyuk Yu.A., Yureneva S.V., Dubrovina A.V. The experience of sibutramine administration in patients with obesity and controlled arterial hypertension. Ozhireniye i metabolism = Obesity and Metabolism. 2019;16(2):42-48. [In Russian]. https://doi.org/10.14341/omet9789
27. Vasyuk Yu.A., Shupenina E.Yu., Nesterova E.A., Golubkova E.I., Nesvetov V.V. Combination of azilsartan medoxomil and chlorthalidone: is it possible to fight systemic hypertension and obesity together? Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2017;22(8):102-106. [In Russian].doi.10.15829/1560-4071-2017-8-102-106